A 12-month, Randomized, Double-masked, Multicenter, Laser-controlled Phase III Study Assessing the Efficacy and Safety of 0.5 mg Ranibizumab Dosed PRN in Subjects With Visual Impairment Due to Diabetic Macular Edema in Chinese Patients
Phase of Trial: Phase III
Latest Information Update: 31 Mar 2017
At a glance
- Drugs Ranibizumab (Primary)
- Indications Diabetic macular oedema; Vision disorders
- Focus Registrational; Therapeutic Use
- Sponsors Novartis
- 29 Mar 2017 Status changed from active, no longer recruiting to completed.
- 26 Oct 2016 Planned End Date changed from 1 Mar 2017 to 1 Jan 2017.
- 26 Oct 2016 Planned primary completion date changed from 1 Mar 2017 to 1 Jan 2017.